Evaluation of "PreCut-Papillectomy" in Difficult Biliary Cannulation
Launched by KLINIKEN LUDWIGSBURG-BIETIGHEIM GGMBH · Mar 7, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method called "PreCut-Papillectomy" to help doctors access the bile duct during a procedure known as endoscopic retrograde cholangiography (ERC). This procedure is important for diagnosing and treating issues related to the bile duct, but sometimes, it can be difficult to reach the bile duct. The trial aims to see if this new technique can make it easier and safer for patients who face challenges with this process.
To participate in the trial, patients must be between the ages of 65 and 74 and must have experienced difficulty in accessing the bile duct. However, individuals who have had certain surgeries affecting their upper digestive tract, previous similar procedures, or specific health conditions may not be eligible. Those who join the trial can expect to undergo the PreCut-Papillectomy procedure, and researchers will closely monitor their experiences to gather important information about its effectiveness and safety. This study is not yet recruiting participants, but it represents a potential advancement in treating patients with difficult bile duct access.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Difficult cannulation of bile duct
- Exclusion Criteria:
- • post-surgical upper GI anatomy
- • previous endoscopic retrograde cholangiopancreaticography or percutaneous transhepatic cholangiography
- • papilla within a diverticulum
- • coagulation disorder
About Kliniken Ludwigsburg Bietigheim Ggmbh
Kliniken Ludwigsburg-Bietigheim gGmbH is a leading healthcare provider in Germany, dedicated to delivering high-quality medical services across a range of specialties. With a focus on patient-centered care and clinical excellence, the organization actively engages in innovative research and clinical trials to advance medical knowledge and improve treatment outcomes. Committed to fostering collaboration among healthcare professionals, researchers, and patients, Kliniken Ludwigsburg-Bietigheim gGmbH plays a pivotal role in the development of new therapies and healthcare solutions, ensuring adherence to rigorous ethical and scientific standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported